Preclinical studies of the falnidamol as a highly potent and specific active ABCB1 transporter inhibitor.

Background: ABCB1 overexpression is a key factor in causing multidrug resistance (MDR). As a result, it is crucial to discover effective medications against ABCB1 to overcome MDR. Falnidamol, a tyrosine kinase inhibitor (TKI) targeting the epidermal growth factor receptor (EGFR), is currently in phase 1 clinical trials for the treatment of solid tumors.

[Alpha-bisabolol reverses ABCB1-mediated multidrug resistance in tumor and its mechanisms].

Objective To investigate whether alpha-bisabolol can effectively reverse ATP binding cassette subfamily B member 1 (ABCB1)-mediated multidrug resistance (MDR) in tumors and to explore the underlying mechanisms. Methods The network pharmacology was utilized to analyze the active components of Agrimonia Eupatoria, predict target genes, and perform GO and KEGG pathway analysis. Molecular docking and thermal stability assays were conducted to examine the interaction between alpha-bisabolol and ABCB1.